Skip to main content
. Author manuscript; available in PMC: 2016 Sep 13.
Published in final edited form as: J Control Release. 2013 Aug 23;172(1):179–189. doi: 10.1016/j.jconrel.2013.08.015

Figure 6. The evaluation of biodistribution and transfection efficiency of the LHH-NP in vivo.

Figure 6

a) Biodistribution profiles of Tex-red labeled dsODN in major organs of H460 xenograft bearing nude mice 4 h post-administration of LHH-NP. The NPs predominately accumulated in the liver, kidneys and tumors after IV injection. b) Confocal microscopic images of tumor cryosections after systemic delivery of LHH-NP encapsulating Texas-red labeled dsODNs. c) Quantification of LHH biodistribution by tracking 3H labeled dsODNs 4 h post-injection (n=3). There was ~5% injected dose per gram tissue accumulated in the tumor. Error bars show mean ± s.d. d) In vivo luciferase gene silencing effects 24 h after IV injection of LHH and LPH NPs to the H460-luc bearing nude mice (0.25mg/kg) (n=3). siRNA delivered by LHH-NP resulted in significantly higher silencing effect than that of LPH-NP. Error bars show mean ± s.d. Student t-test.